Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus–induced type 2 responses and immunopathology

Abstract

Capsule Summary GLP-1R signaling, an emerging anti-inflammatory therapeutic 59 target, 60 attenuated type 2-associated immunopathology in mice infected with a strain of RSV that was 61 isolated from a hospitalized infant with severe lower respiratory tract infection and bronchiolitis.

Dissecting the interaction between COVID‐19 and diabetes mellitus

“…There is emerging evidence of the potential anti-inflammatory properties arising from glucagon-like peptide-1 (GLP-1) receptor signaling 38 . GLP-1 receptor agonist treatment in mice infected with respiratory syncytial virus is associated with a significant reduction in inflammatory cytokine production and attenuation of inflammation in the respiratory epithelium 39 . Furthermore, GLP-1 receptor agonist therapy in the intensive care unit setting is associated with a reduction of hypoglycemia, glucose variability and catabolism by suppressing glucagon 40 , all of which can be protective in these critically ill patients.…”

Endocrine Conditions and COVID-19

“…2 and ▶3) [21]. While the benefits of DPP-4 inhibition are unproven, there is a clear anti-inflammatory and lung-protective effect of GLP-1 receptor analogues in obesity that may prove useful in mitigating risks for severe disease [71,125]. Furthermore, co-existing obesity hypoventilation syndrome and obstructive sleep apnea, both complications of obesity, may compromise respiratory function that could also account for the observed effects.…”

Severity of allergic rhinitis assessed by using urine metabolomic profiling: Proof of concept

“…Graphic presentation of the separation between groups in the model (TNSS, 0 or 12) or test subjects with intermediate TNSSs (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11) are shown by their respective PLS-DA scores (Fig 1, C). There is a stepwise change in prediction score as the severity of the nasal symptoms increase.…”

“…Whole blood BATs and mast cell activation tests (MATs) to peanut were performed, as previously described. 3,9 Statistical analyses were performed with SAS 9.4 software (SAS Institute, Cary, NC) and JMP Pro software, Version 13.2.1. Depending on data distribution, nonparametric Wilcoxon tests or normality-based t tests were used, where specified.…”